Literature DB >> 26001595

High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.

Fatjon Leti1, Ivana Malenica1, Meera Doshi1, Amanda Courtright1, Kendall Van Keuren-Jensen1, Christophe Legendre1, Christopher D Still2, Glenn S Gerhard3, Johanna K DiStefano4.   

Abstract

Recent evidence suggests that microRNAs (miRNAs), small, noncoding RNA molecules that regulate gene expression, may play a role in the regulation of metabolic disorders, including nonalcoholic fatty liver disease (NAFLD). To identify miRNAs that mediate NAFLD-related fibrosis, we used high-throughput sequencing to assess miRNAs obtained from liver biopsies of 15 individuals without NAFLD fibrosis (F0) and 15 individuals with severe NAFLD fibrosis or cirrhosis (F3-F4), matched for age, sex, body mass index, type 2 diabetes status, hemoglobin A1c, and use of diabetes medications. We used DESeq2 and Kruskal-Wallis test to identify miRNAs that were differentially expressed between NAFLD patients with or without fibrosis, adjusting for multiple testing using Bonferroni correction. We identified a total of 75 miRNAs showing statistically significant evidence (adjusted P value <0.05) for differential expression between the 2 groups, including 30 upregulated and 45 downregulated miRNAs. Quantitative reverse-transcription polymerase chain reaction analysis of selected miRNAs identified by sequencing validated 9 of 11 of the top differentially expressed miRNAs. We performed functional enrichment analysis of dysregulated miRNAs and identified several potential gene targets related to NAFLD-related fibrosis including hepatic fibrosis, hepatic stellate cell activation, transforming growth factor beta signaling, and apoptosis signaling. We identified forkhead box O3 and F-box WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7) as potential targets of miR-182, and found that levels of forkhead box O3, but not FBXW7, were significantly decreased in fibrotic samples. These findings support a role for hepatic miRNAs in the pathogenesis of NAFLD-related fibrosis and yield possible new insight into the molecular mechanisms underlying the initiation and progression of liver fibrosis and cirrhosis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26001595      PMCID: PMC4537840          DOI: 10.1016/j.trsl.2015.04.014

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  41 in total

1.  Collagen/silk fibroin bi-template induced biomimetic bone-like substitutes.

Authors:  Jianglin Wang; Wei Zhou; Wei Hu; Lei Zhou; Shenqi Wang; Shengmin Zhang
Journal:  J Biomed Mater Res A       Date:  2009-08-24       Impact factor: 4.396

2.  Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice.

Authors:  Igor P Pogribny; Athena Starlard-Davenport; Volodymyr P Tryndyak; Tao Han; Sharon A Ross; Ivan Rusyn; Frederick A Beland
Journal:  Lab Invest       Date:  2010-06-14       Impact factor: 5.662

3.  An SREBP-responsive microRNA operon contributes to a regulatory loop for intracellular lipid homeostasis.

Authors:  Tae-Il Jeon; Ryan M Esquejo; Manuel Roqueta-Rivera; Peter E Phelan; Young-Ah Moon; Subramaniam S Govindarajan; Christine C Esau; Timothy F Osborne
Journal:  Cell Metab       Date:  2013-07-02       Impact factor: 27.287

4.  MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice.

Authors:  Angela Dolganiuc; Jan Petrasek; Karen Kodys; Donna Catalano; Pranoti Mandrekar; Arumugam Velayudham; Gyongyi Szabo
Journal:  Alcohol Clin Exp Res       Date:  2009-07-01       Impact factor: 3.455

5.  The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice.

Authors:  Guo-Ping Tian; Yan-Yan Tang; Ping-Ping He; Yun-Cheng Lv; Xin-Pin Ouyang; Guo-Jun Zhao; Shi-Lin Tang; Jian-Feng Wu; Jia-Lin Wang; Juan Peng; Min Zhang; Yuan Li; Francisco S Cayabyab; Xi-Long Zheng; Da-Wei Zhang; Wei-Dong Yin; Chao-Ke Tang
Journal:  Biochem Biophys Res Commun       Date:  2013-12-02       Impact factor: 3.575

6.  An electronic health record-enabled obesity database.

Authors:  G Craig Wood; Xin Chu; Christina Manney; William Strodel; Anthony Petrick; Jon Gabrielsen; Jamie Seiler; David Carey; George Argyropoulos; Peter Benotti; Christopher D Still; Glenn S Gerhard
Journal:  BMC Med Inform Decis Mak       Date:  2012-05-28       Impact factor: 2.796

7.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

8.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

9.  Deletion of hepatic FoxO1/3/4 genes in mice significantly impacts on glucose metabolism through downregulation of gluconeogenesis and upregulation of glycolysis.

Authors:  Xiwen Xiong; Rongya Tao; Ronald A DePinho; X Charlie Dong
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

10.  Deep sequencing of small RNA repertoires in mice reveals metabolic disorders-associated hepatic miRNAs.

Authors:  Tingming Liang; Chang Liu; Zhenchao Ye
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

View more
  32 in total

Review 1.  Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis.

Authors:  Johanna K DiStefano
Journal:  Cell Mol Life Sci       Date:  2020-06       Impact factor: 9.261

2.  Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.

Authors:  Amanda Hanson; Ignazio S Piras; Danielle Wilhelmsen; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano
Journal:  Cytokine       Date:  2019-07-25       Impact factor: 3.861

3.  Primate fetal hepatic responses to maternal obesity: epigenetic signalling pathways and lipid accumulation.

Authors:  Sobha Puppala; Cun Li; Jeremy P Glenn; Romil Saxena; Samer Gawrieh; Amy Quinn; Jennifer Palarczyk; Edward J Dick; Peter W Nathanielsz; Laura A Cox
Journal:  J Physiol       Date:  2018-04-06       Impact factor: 5.182

4.  Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD.

Authors:  J Latorre; J M Moreno-Navarrete; J M Mercader; M Sabater; Ò Rovira; J Gironès; W Ricart; J M Fernández-Real; F J Ortega
Journal:  Int J Obes (Lond)       Date:  2017-01-25       Impact factor: 5.095

5.  Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells.

Authors:  Fatjon Leti; Christophe Legendre; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano
Journal:  Transl Res       Date:  2017-09-19       Impact factor: 7.012

Review 6.  Circulating microRNAs in nonalcoholic fatty liver disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-15       Impact factor: 3.869

7.  Hepatic expression profiling identifies steatosis-independent and steatosis-driven advanced fibrosis genes.

Authors:  Divya Ramnath; Katharine M Irvine; Samuel W Lukowski; Leigh U Horsfall; Zhixuan Loh; Andrew D Clouston; Preya J Patel; Kevin J Fagan; Abishek Iyer; Guy Lampe; Jennifer L Stow; Kate Schroder; David P Fairlie; Joseph E Powell; Elizabeth E Powell; Matthew J Sweet
Journal:  JCI Insight       Date:  2018-07-26

Review 8.  MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.

Authors:  Zhiqiang Fang; Guorui Dou; Lin Wang
Journal:  Int J Biol Sci       Date:  2021-04-29       Impact factor: 6.580

Review 9.  MicroRNAs in Nonalcoholic Fatty Liver Disease.

Authors:  György Baffy
Journal:  J Clin Med       Date:  2015-12-04       Impact factor: 4.241

10.  Association of Circulating Serum miR-34a and miR-122 with Dyslipidemia among Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Noel C Salvoza; David C Klinzing; Juliet Gopez-Cervantes; Michael O Baclig
Journal:  PLoS One       Date:  2016-04-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.